大肠癌SELDI-TOF-MS蛋白质组图谱的分析

Analysis of protein patterns in serum from patients with colorectal cancer by SELDI-TOF-MS

目的:筛选并建立大肠癌血清蛋白质组图谱的诊断模型并探究其临床价值。方法:将102例血清标本(大肠癌53例,正常对照49例)随机分成训练组75例,测试组27例。用CM10蛋白芯片及SELDI-TOF-MS技术对训练组75例血清标本(大肠癌37例,正常对照38例)进行蛋白质组图谱检测,经留一法交叉验证后建立诊断模型,并对测试组27例未知的血清进行血清蛋白质谱测定,盲法验证该模型。结果:通过ZUCI-蛋白芯片数据分析系统软件包运算,用6个质荷比峰(3 951.147 3、4 364.486 5、5 926.628 6、8 103.635 6、8 964.429 9、11 709.016 8m/z)建立了大肠癌蛋白质组图谱诊断模型,经过交叉验证其准确度96.00%,灵敏度94.59%,特异度97.37%,阳性预测值97.22%。经盲法验证该方法的检出率为81.25%,排除率为100%。结论:本组建立的诊断模型可以有效区分大肠癌和非癌正常人,为大肠癌的诊断与筛查提供了一条崭新途径。

Objective： To analyze the alterations of serum protein patterns from patients with coloreetal cancer （CRC） by SELDI-TOF-MS （surface-enhanced laser desorption/ionization time of flight mass spectrometry）, screen and build diagnosis model of CRC and investigate its clinical value. Methods： One hundred and two serum samples （53 CRC. patients and 49 healthy individuals） were randomly divided into training set （n =75, 37 CRC. patients and 38 healthy individuals） and test set （n =27）. SELDI-TOF-MS and CM10 protein chip were used to detect the serum protein patterns of training set. The data was analyzed and the diagnostic model was established by using ZUCI-protein chip data analyze system software package. The diagnostic model was evaluated and validated by leave one cross validation. The classifier was then challenged with the test set. Results： A diagnostic model consisting of six protein peaks（3 951. 147 3, 4 364. 486 5, 5 926. 628 6, 8 103. 6356, 8 964. 429 9, 11 709. 016 8 m/z） could do the best in the diagnosis between colorectal cancer and controls. Its accuracy was 96.00 %, sensitivity was 94.59%, specificity was 97.37% and positive value was 97.22%. By blind examination in test set, the corresponding accuracy was 81.25% （13/16）, the corresponding sensitivity was 100% （11/11）. Conclusion： The diagnostic model formed by six protein peaks can do the best in discriminating colorectal cancer from controls. It provides a new approach for diagnosing and screening colorectal cancer.